SFW Capital Partners Closes on over $345 Million for its Second Fund Specializing in Analytical Tools and Related Services

SFW Capital Partners Closes on over $345 Million for its Second Fund Specializing in Analytical Tools and Related Services

Hits Hard Cap on Fundraising in Under Six Months

May 06, 2015 06:00 AM Eastern Daylight Time

RYE, N.Y.--()--SFW Capital Partners ("SFW"), a private equity firm specializing in Analytical Tools and Related Services, today announced the final close of SFW Capital Partners Fund II, LP ("the Fund") and its related entities with total commitments of over $345 million, including a significant investment from SFW professionals. The Fund closed at its hard cap.

SFW focuses on making strategic investments in mid-size Analytical Tools and Related Services companies, including providers of instrumentation, information and software, and related business services, a sector that the SFW team has invested in for over 20 years. Analytical Tools and Related Services businesses provide information, data, and analytics that support research, product development, process control, quality assurance, compliance, diagnostics, sales and marketing, and other critical decision-making processes across all major industries.

Prior SFW fund investments include AgData (a provider of strategic data, software, and analytical solutions to the world's largest agricultural and animal health manufacturers), MD Buyline (a provider of information, software tools, and analytical solutions on medical technology, consumables and outsourced services to healthcare providers), Spectro Scientific (a provider of fluid analysis instruments and software for evaluating machine and/or process conditions in the field, lab, and mobile applications), Buyers Laboratory (a provider of test-based analytical information and software tools to the digital imaging industry), filtec (a provider of advanced in-line inspection instrumentation, software, and systems for the global beverage industry), and Essen BioScience (a provider of instrumentation, software, and reagents used for live cell imaging in life science research applications).

"We are very gratified to have the continued support of an exceptional group of limited partners, including highly regarded foundations, endowments, family offices, and select fund of funds, who appreciate our specialization in the Analytical Tools and Related Services sector and disciplined, focused investment strategy," said SFW Partner Roger Freeman. "We believe our deep experience and specialization uniquely enables us to partner with management teams to build fundamental, lasting value in Analytical Tools companies."

SFW intends to continue the highly disciplined, systematic investment strategy that the SFW team has developed over the past 20 years. SFW seeks to apply its experience and resources to enable middle market Analytical Tools companies with differentiated products and services, solid market positions, and proprietary product technologies, analytical techniques, or information gathering capabilities to reach their full potential. As with SFW's previous fund, SFW Fund II will seek to make equity investments of $10 million to $75 million.

"Our specialized approach has enabled us to work collaboratively with strong managers to build significant value in the companies in which we invest," said SFW Partner Roger Freeman. "We look forward to continuing to apply this same strategy of working with leading managers to build exceptional Analytical Tools companies."

SFW did not use a placement agent. Kirkland & Ellis LLP served as fund formation counsel.

About SFW Capital Partners

SFW Capital Partners is a Leading Investor in Analytical Tools and Related Services Companies, including providers of instrumentation, information and software, and related business services. SFW is a specialized private equity firm that exclusively invests where its 20+ years of knowledge of the relevant business models, technology, competitive dynamics and service requirements gives it a unique ability to support management teams in growing their companies and building value. For more information, please visit www.sfwcap.com.

Contacts

BackBay Communications
Doug Allen, 212-520-1385, ext. 5
[email protected]

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.